Scientific Advisory Board

Jeff Kelly


Jeff is Professor and Chair of Molecular and Experimental Medicine at The Scripps Research Institute. An expert on protein misfolding and amyloid-targeted drug discovery, he is a founder of FoldRx and an inventor of tafamidis, the first disease-modifying drug targeting an amyloidogenic protein. Tafamidis has been appoved in Europe (2011) and Japan (2013) and is currently under review by the FDA for the clinical treatment of transthyretin amyloidosis. 

Usha Andley


Usha is a Professor in the Department of Ophthalmology and Visual Sciences at Washington University. Usha is an expert on the role of crystallins in cataracts and the biochemical basis of human cataract formation.

Stan Prusiner


Stan is Director of the Institute for Neurodegenerative Diseases and a Professor of Neurology at the University of California at San Francisco. Stan is an expert in protein misfolding pathology. His contributions have been recognized with numerous awards, including the Nobel Prize in Physiology or Medicine for his discovery of prions. 

Richard Labaudiniere


Richard is the former CEO and President of FoldRx, a company focused on protein misfolding diseases, which was acquired by Pfizer in 2010. Richard has deep expertise in medicinal chemistry.